FIMECS Appoints Mr. Masanobu Yatabe as Chief Financial Officer
News release Download PDF
Kanagawa, Japan, 31, Mar 2023 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Mr. Masanobu Yatabe to the role of Chief Financial Officer. Mr. Masanobu Yatabe has more than 25 years of experience in a securities firm and more than 5 years of industry experience in the listed and private companies as a board of director. He will contribute to build up a department of general administration. Mr. Sho Sawada, former Chief Financial Officer resigned from FIMECS.
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/
# # #
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan